Champions Oncology Overview
Valuation check: CSBR's P/E ratio is -61.63, below the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow-61.63
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Champions Oncology (CSBR) currently reports a P/E ratio of -61.63. That is below the Healthcare sector average of 25.9. Use the charts on this page to explore Champions Oncology's P/E ratio history and peer comparisons.
Champions Oncology's P/E ratio of -61.63 is lower than the Healthcare sector average of 25.9. That is roughly 338.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Champions Oncology's market price to a fundamental measure such as earnings, sales, or book value. At -61.63, CSBR can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -61.63, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Champions Oncology, and consider following CSBR for alerts when major investors trade the stock.
Champions Oncology is classified in the Healthcare sector. On P/E ratio, it currently shows -61.63 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CSBR with unrelated industries.
